Stockscreener 앱 받기
27.92
0.75%
-0.21
시간 외 거래:
27.92
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Agios Pharmaceuticals (AGIO) reports Q4 loss, beats revenue estimates - MSN
Sickle Cell Disease Market: Investment-Ready Growth Trends to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics Inc., Graphite Bio, Roche, Quercis - Barchart.com
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
ATTENTION AGIO SHAREHOLDERS: Investors who lost money on Agios Pharmaceuticals, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - PR Newswire
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gro - GuruFocus
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact The Gross Law Firm Regarding an Ongoing Investigation - PR Newswire
Liquidity Mapping Around (AGIO) Price Events - Stock Traders Daily
HighVista Strategies LLC Buys 125,171 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Does UAE Thalassemia Approval for PYRUKYND Reframe the Bull Case for Agios Pharmaceuticals (AGIO)? - simplywall.st
Agios Pharmaceuticals (NASDAQ:AGIO) Cut to Sell at Wall Street Zen - MarketBeat
Cantor Fitzgerald Keeps Overweight on Agios Pharmaceuticals, Inc. (AGIO) Mar 2026 - Meyka
AGIO SEC FilingsAgios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Agios Pharmaceuticals (AGIO) price target decreased by 34.97% to 32.77 - MSN
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND Approval And GCC Expansion - simplywall.st
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - Morningstar
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law ViolationsContact The Gross Law Firm for Details- AGIO - lelezard.com
Agios Pharmaceuticals, Inc. Investigated Regarding Potential Sec - GuruFocus
Agios Pharmaceuticals (AGIO) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Agios (NASDAQ: AGIO) executive sells 2,959 shares to cover RSU tax - Stock Titan
Agios Pharmaceuticals: Worthy Of Accumulation (NASDAQ:AGIO) - Seeking Alpha
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides - AOL.com
Zacks Research Analysts Lift Earnings Estimates for AGIO - MarketBeat
Stock Analysis: Is Agios Pharmaceuticals Inc. stock showing strong momentum2026 Fundamental Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
AGIO Earnings History & Surprises | EPS & Revenue Results | AGIOS PHARMACEUTICALS INC (NASDAQ:AGIO) - ChartMill
Why Agios Pharmaceuticals Inc. stock could benefit from AI revolutionShort Setup & Risk Managed Investment Entry Signals - Naître et grandir
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
FY2028 Earnings Forecast for AGIO Issued By Zacks Research - MarketBeat
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Why (AGIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell Alert: Washburn Theodore James Jr. Sells Shares of Agios Pharmaceuticals Inc (AGIO) - GuruFocus
AGIO: Citigroup Raises Price Target Amidst Continuous Buy Ratings | AGIO Stock News - GuruFocus
Citigroup Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock - MarketBeat
Agios Pharmaceuticals (AGIO) Target Price Raised by Citi - GuruFocus
2,959 AGIO shares tied to RSU vesting (NASDAQ: AGIO) — Form 144 - Stock Titan
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors o - GuruFocus
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets - Yahoo Finance
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO – Company AnnouncementFT.com - Financial Times
Agios Pharmaceuticals, Inc. $AGIO Shares Sold by TD Asset Management Inc - MarketBeat
Agios Pharmaceuticals (AGIO) Is Down 6.3% After UAE Clears PYRUKYND As First Thalassemia Drug - simplywall.st
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact The Gross Law Firm Regarding Potential Securities Law ViolationsAGIO - StreetInsider
Agios (AGIO) CMO logs tax-driven share sales and major new equity awards - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives large equity grants, sells shares for tax withholding - Stock Titan
AGIOS (AGIO) legal chief gains RSUs, options and sells shares for taxes - Stock Titan
Agios Pharmaceuticals (AGIO) CFO equity grants and tax-driven sales - Stock Titan
AGIOS (NASDAQ: AGIO) CCO reports new equity awards and tax-driven share sales - Stock Titan
Agios (AGIO) accounting officer sells shares to cover RSU tax withholding - Stock Titan
Agios (NASDAQ: AGIO) executive granted 14,000 RSUs and 52,000 options - Stock Titan
AGIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights A - GuruFocus
Agios Pharmaceuticals Highlights 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction - National Today
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction - Yahoo Finance
A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND UAE Thalassemia Approval - simplywall.st
AGIO (Nasdaq: AGIO) reports RSU vesting and Brian Goff sale disclosure - Stock Titan
AGIO (NASDAQ: AGIO) insider resale notice for 5,218 shares on 03/02/2026 - Stock Titan
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Insider sale notice: 5,035 AGIO shares tied to RSU vesting (NASDAQ: AGIO) - Stock Titan
Insider sells and RSUs vest at AGIO (NASDAQ: AGIO) — 2,868 RSUs listed - Stock Titan
AGIO: Mitapivat’s thalassemia launch accelerates, with pipeline and regulatory catalysts ahead - TradingView
Agios' Pyrukynd® (mitapivat) approved for adults with thalassemia in the United Arab Emirates - marketscreener.com
1.20%
0.06%
자본화:
|
볼륨(24시간):